NCT03114527 2025-04-04
Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
Fox Chase Cancer Center
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT01275222 2021-06-25
Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors
Novartis
Phase 1/2 Completed
NCT01804374 2015-06-17
SERIO
Italian Sarcoma Group
Phase 2 Completed
NCT00187174 2015-03-04
Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors
St. Jude Children's Research Hospital
Phase 1 Completed
NCT01281865 2014-10-08
Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01048723 2013-12-16
Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00927966 2013-11-14
RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01830153 2013-04-12
RAD001 in Advanced Sarcoma
Asan Medical Center
Phase 2 Completed
NCT01216839 2013-03-26
Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas
Hospital Santa Marcelina
Phase 2 Unknown